R1 Therapeutics
PrivateLast Round
Series A
Mar 17, 2026
Total Funding Raised
$77.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
R1 Therapeutics operates in Healthcare & Life Sciences and is based in Redwood City, California. Its latest recorded funding round was a Series A round in March 2026.
R1 Therapeutics is a biotechnology company that develops first-in-class therapies for patients with kidney disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
R1 Therapeutics Comparables
Compare R1 Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mironid | 80% | |
| Borealis Biosciences | 79% | |
| Novartis | 74% |
For institutional investors. Book with your work email.
R1 Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
R1 Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SymBiosis Capital Management | Series A |
| Abingworth | Series A |
| F-Prime Capital | Series A |
| DaVita Venture Group | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 112% MoM, reaching 2.6K.
- Aug 15, 2026
Grew 23% QoQ, from 13 to 16 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 15, 2026
R1 Therapeutics, Inc. presents a trial-in-progress poster outlining the global Phase IIb multi-regional clinical trial design for AP306 at ASN Kidney Week 2026 in Colorado on Oct 22nd '26.
- is_developingSep 30, 2026
R1 Therapeutics, Inc. is developing AP306 as an investigational monotherapy that acts locally in the gastrointestinal tract to inhibit active phosphate transport, with continued development supported through its global Phase 2b program.
- receives_financingSep 30, 2026
R1 Therapeutics, Inc. raised $80.5M in a Series A Plus from Co-Founder to support its development of kidney disease therapies in California.
For institutional investors. Book with your work email.
R1 Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about R1 Therapeutics's valuation, stock price, and market status.
Is R1 Therapeutics a public or private company?
R1 Therapeutics is a private company.
What is the current stock price of R1 Therapeutics?
R1 Therapeutics is a private company, so its shares have no public market price. Caplight tracks R1 Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is R1 Therapeutics worth (valuation)?
Valuation information for R1 Therapeutics is not publicly available.
Can I buy R1 Therapeutics stock?
R1 Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was R1 Therapeutics's last funding round?
R1 Therapeutics's most recent funding round was Series A on March 17, 2026.
Who are the main investors in R1 Therapeutics?
Key investors in R1 Therapeutics include Abingworth, F-Prime Capital, DaVita Venture Group.
Will R1 Therapeutics IPO soon?
No public IPO plans have been announced for R1 Therapeutics.
How can I track R1 Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in R1 Therapeutics's shares on secondary markets.